- US indices retreat from recent highs after a strong rally into year-end. The US100 leads declines, falling 0.7% amid semiconductor sector weakness. US500 drops 0.4% while US30 loses 0.2%. On the positive side, Mexican MEXComp gains 1.45% and BRAComp advances 1.06%. The VIX fear gauge holds steady around 16.03.
- European markets show mixed sentiment. FRA40 advances 0.71% to 7491.2, followed by UK100 gaining 0.54% to 8359.5. The DE40 declines 0.20% to 20367.8, while VSTOXX volatility index drops 0.67% to 14.78. Other notable movers include NED25 (+0.55% to 895.91), SPA35 (-0.42% to 12006), and ITA40 (-0.57% to 34585).
- Nvidia shares tumble 2% after China's market regulator launches antitrust probe into the company's AI chip market dominance. The investigation focuses on potential monopolistic practices, with Chinese revenues representing 15% of Nvidia's Q3 earnings.
- Apollo Global Management and Workday set to join S&P 500, replacing Qorvo and Amentum Holdings. Mondelez explores potential Hershey acquisition in deal that could create $50 billion food giant.
- European economic data disappoints as Sentix Investor Confidence falls to -17.5 vs -12.3 expected, highlighting continued weakness. Swiss consumer confidence improves to 49.4 from 47.4.
- Energy commodities surge with NATGAS leading (+3.77% to 3.197), followed by GASOLINE (+2.75% to 195.37) and OIL.WTI (+2.11% to 68.59). Precious metals also advance: SILVER (+3.07% to 31.922), PALLADIUM (+2.57% to 971.4), GOLD (+1.16% to 2662.44).s
- Dollar trades flat while Treasury yields rise 4bps to 4.19%. EUR/USD steady at 1.0571, GBP/USD gains 0.3% to 1.2776, and USD/JPY climbs 0.8% to 151.27.
- Cryptocurrencies under pressure with Bitcoin falling 2.6% to $97,525 and Ethereum dropping 3.8% to $3,841. MicroStrategy announces $2.1B additional Bitcoin purchase.
- Market focus shifts to Wednesday's CPI data, with core inflation expected at +0.3% MoM and +3.3% YoY. Markets price 85.8% probability of December Fed rate cut.
Daily Summary: As a ceasefire drifts away, markets lose ground
Warsh before the Senate: “I will not be a tool of the president” and signals Fed reform agenda
UnitedHealth Group earnings: Healthy growth
US Open: Macro Up, Tensions Down!
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
